The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy

Bullous Keratopathy Clinical Trial

— C3R  

Official title:

Study of the Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01106274
• Other study ID #: MUMS-88191
• Status: Completed
• Phase: N/A
• First received: April 16, 2010
• Last updated: April 16, 2010
• Start date: November 2008
• Est. completion date: September 2009

Study information

• Verified date: October 2008
• Source: Mashhad University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Iran: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Recently, riboflavin (0.1%) and ultraviolet-A (UVA) collagen cross-linking (C3R) has shown potential to improve the signs and symptoms of bullous keratopathy .The objective of this study is to demonstrate the effects of C3R to treat bullous keratopathy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients with bollous keratopathy

Exclusion Criteria:

• corneal scarring or contemporary eye disease affecting VA were excluded.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bullous Keratopathy

Intervention

Radiation:
• ultraviolet-A
Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mashhad University of Medical Sciences